Journal of Nuclear Medicine publishes NCI-sponsored guidelines for using FDG PET

Reston, Va.--Publication of consensus recommendations for the use of positron emission tomography (PET) imaging--with the radiotracer fluorodeoxyglucose (FDG)--in National Cancer Institute trials will go a long way in helping physicians and scientists determine ways to manage cancer and promote drug development in the future. The recommendations, published in the June issue of the Journal of Nuclear Medicine, focus on the practical aspects of FDG PET (patient preparation; image acquisition, reconstruction and analysis; and quality assurance) and provide a valuable reference for incorporating PET into clinical trials.

"There should be less variability in the performance of FDG PET in clinical trials by enacting these recommendations," explained principal author Lalitha K. Shankar, NCI medical officer at the Cancer Imaging Program. "This would help speed the evaluation of FDG PET as a biomarker. If FDG PET, as is hoped, proves to be a useful biomarker in certain cancers--such as lymphoma, lung and breast cancer among others--this could potentially result in shorter clinical trials in these malignancies and improved therapy for patients with these cancers," she said. These guidelines, drafted by PET experts at various universities and institutes in the United States and abroad, represent a step toward qualifying FDG PET as a biomarker or biologic indicator to assess cancer treatment response.

"To date, there has been no significant agreement on the best methodology for obtaining or analyzing 18F-FDG PET. Standard protocols needed to be developed so that data about the effectiveness of FDG PET as an indicator of treatment response in patients could be collected and compared," Shankar added. Publication of the consensus recommendations is the culmination of attempts to reach agreement between physician and scientist members of the imaging community on certain basic issues regarding the acquisition and analysis of these scans, she said.


Contact: Maryann Verrillo
Society of Nuclear Medicine

Page: 1 2

Related biology news :

1. News tips from the Journal of Neuroscience
2. News tips from the Journal of Neuroscience
3. News tips from the Journal of Neuroscience
4. News tips from the Journal of Neuroscience
5. Tips from the Journals of the American Society for Microbiology
6. Journalists can register now for ECCO 14 -- the European Cancer Conference
7. Journal of Alzheimers Disease achieves significant impact factor
8. News tips from the Journal of Neuroscience
9. Highlights from the July 2007 Journal of the American Dietetic Association
10. News tips from the Journal of Neuroscience
11. Journal of Nuclear Medicines impact grows, remains consistently high over past 5 years

Post Your Comments:

(Date:5/28/2020)... ... ... CrucialTrak, a global designer and manufacturer of biometric access control systems, today ... and sell its complete line of biometric readers and access gates . CEG ... . , Brett Mason, CrucialTrak’s Director of Channel Sales for the Americas is ...
(Date:5/28/2020)... ... May 28, 2020 , ... ... solution for adjunct liquefaction: AMYLEX® 6T. The innovative enzyme enables numerous business ... new segments with locally-sourced raw materials, improve productivity, maximize yield, ensure consistent ...
(Date:5/26/2020)... , ... May 26, 2020 ... ... enterprise software solutions for biopharmaceutical R&D, today announced that Gritstone Oncology, Inc., ... receptor (TCR)-mimetic bispecific T cell engagers and TCR-based therapeutics, has implemented ...
Breaking Biology News(10 mins):
(Date:5/21/2020)... REDWOOD CITY, Calif. (PRWEB) , ... May 20, ... ... to announce the addition of Simon Prakash, who will serve as the company’s ... Simon joins at a time when Exo is disrupting the medical imaging space, ...
(Date:5/15/2020)... ... May 14, 2020 , ... Children with defective ... surgeries before becoming adults. The reason: there are no heart valve prosthetics ... need, the Department of Defense has awarded Draper, Boston Children’s Hospital and Seattle ...
(Date:5/15/2020)... ... May 15, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Ganz as Executive Chairman. Mr. Ganz will continue to lead Sentien’s Board of ... work closely with CEO Brian Miller and Sentien’s management team. , Mr. ...
(Date:5/14/2020)... , ... May 12, 2020 , ... ... for translational research, is bringing together thousands of industry leaders, clinicians, research scientists, ... highlights two plenary speakers, Carl June, MD, Director of the Center for Cellular ...
Breaking Biology Technology:
Cached News: